Long-Term Clinical Effectiveness of Ustekinumab in Patients With Crohn's Disease: A Retrospective Cohort Study

Takahiro Ito; Atsuo Maemoto; Takehiko Katsurada; Hiroki Tanaka; Satoshi Motoya; Nobuhiro Ueno; Mikihiro Fujiya; Toshifumi Ashida; Daisuke Hirayama; Hiroshi Nakase

doi:10.1093/crocol/otaa061

Long-Term Clinical Effectiveness of Ustekinumab in Patients With Crohn's Disease: A Retrospective Cohort Study

Crohns Colitis 360. 2020 Jul 28;2(4):otaa061. doi: 10.1093/crocol/otaa061. eCollection 2020 Oct.

Authors

Affiliations

¹ IBD Center, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan.
² Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan.
³ IBD Center, Sapporo-Kosei General Hospital, Sapporo, Japan.
⁴ Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.
⁵ Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan.

Abstract

Background: This study clarifies the long-term effectiveness of ustekinumab based on real-life data from Japanese Crohn's disease (CD) patients.

Methods: A total of 137 patients were included, and 124 patients (90.5%) were exposed to anti-tumor necrosis factor-α agents.

Results: The clinical remission rate at week 52 was 32.4% in moderate to severely active CD patients. The achievement of clinical remission for 8 weeks after ustekinumab therapy induction was associated with clinical remission at week 52. Ustekinumab persistence rate at week 104 was 81.4%.

Conclusion: Ustekinumab is effective and persistent in CD patients with the previous treatment history of several biologics.

Keywords: Crohn’s disease; clinical effectiveness; positive predictors; ustekinumab.